Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | STAT1 | P42224 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23714371 | 0.91 | APP (0.34) | APPCYP1A2NPC1MAPTRAB9A | |
| SCHEMBL23619139 | 0.90 | APP (0.37) | APPCYP1A2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30060266 | 0.90 | APP (0.37) | APPCYP1A2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23701702 | 0.89 | APP (0.36) | APPCYP1A2 | |
| SCHEMBL30062127 | 0.89 | APP (0.30) | APPCYP1A2 | |
| SCHEMBL21678187 | 0.87 | APP (0.34) | APPCYP1A2NPC1MAPTRAB9A | |
| SCHEMBL21678273 | 0.87 | APP (0.34) | APPCYP1A2NPC1MAPTRAB9A | |
| SCHEMBL23611487 | 0.87 | APP (0.39) | APPCYP1A2NPC1MAPTRAB9A | |
| SCHEMBL30061912 | 0.87 | APP (0.39) | APPCYP1A2NPC1MAPTRAB9A | |
| SCHEMBL23611507 | 0.86 | APP (0.41) | APPCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11492359-B2 | Near-infrared nerve-sparing fluorophores | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-11-08 | — | — | US | disclosed |
| US-20210317137-A1 | NEAR-INFRARED NERVE-SPARING FLUOROPHORES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210317137-A1 | NEAR-INFRARED NERVE-SPARING FLUOROPHORES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210236657-A1 | NERVE-SPECIFIC FLUOROPHORE FORMULATIONS FOR DIRECT AND SYSTEMIC ADMINISTRATION | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210236657-A1 | NERVE-SPECIFIC FLUOROPHORE FORMULATIONS FOR DIRECT AND SYSTEMIC ADMINISTRATION | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-08-05 | — | — | US | disclosed |
| WO-2020033435-A1 | NERVE-SPECIFIC FLUOROPHORE FORMULATIONS FOR DIRECT AND SYSTEMIC ADMINISTRATION | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492359-B2 | Near-infrared nerve-sparing fluorophores | NTRK1, PMP22, GAP43 | APP 1700/4885CYP1A2 1621/4885NPC1 3548/4885 |
| US-20210236657-A1 | NERVE-SPECIFIC FLUOROPHORE FORMULATIONS FOR DIRECT AND SYSTEMIC ADMINISTRATION | PFAS, NPFFR2, NPFFR1 | APP 2082/4885CYP1A2 1363/4885NPC1 1620/4885 |
| US-20210317137-A1 | NEAR-INFRARED NERVE-SPARING FLUOROPHORES | NTRK1, NGF, SMN1; SMN2 | APP 1824/4885CYP1A2 4547/4885NPC1 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.